

*FP7 Cooperation Work Program: Health
Abstract for partner search to Xbrane Bioscience AB*

Xbrane Bioscience AB

About the Company

Xbrane Bioscience AB develops versatile platforms for the efficient and cost-effective production of proteins and vaccines. This SME was founded in early 2008 as a spin-off company from the world-leading Center for Biomembrane Research at the Department of Biochemistry and Biophysics at Stockholm University, Sweden. Xbrane Bioscience develops and commercializes innovations in bacterial protein expression, surface display and secretion.

Research Focus

Xbrane Bioscience has developed the *E.coli* based Xbrane Lemo System™, which conveniently allows optimizing overexpression of any given protein using a single strain rather than a multitude of strains.

Currently, Xbrane Bioscience is engineering platforms for *E.coli* and related bacteria allowing both high-yield protein expression on their cell surface and in the extracellular medium.

For *E.coli* and related bacteria we are developing a versatile cell surface display system that allows the efficient expression of enzymes and epitopes on the cell surface. Our cell surface display system has a high potential for cost-effective and fast development and production of live vaccines – an area we now are focusing on.

Furthermore, a fusion-protein based system is being developed for the efficient secretion of recombinant proteins into the extracellular medium. To date, such a system does not exist for *E.coli* and it is envisaged that it will tremendously facilitate purification of overexpressed proteins and the endotoxin free production of subunit vaccines.

Finally, we are creating the infrastructure for the engineering of protein specific *E.coli* production strains.

Expertise

The company has access to extensive expertise within medical biology, molecular biology and biochemistry, molecular engineering, microbial pathogenesis and molecular genetics. Xbrane Bioscience has extensive collaborations with Dr. Jan-Willem de Gier (Center for Biomembrane Research, Stockholm University, Sweden), Dr. Joen Luirink (Department of Molecular Microbiology, VU University Amsterdam, the Netherlands) and Dr. Samuel Wagner (Section for Microbial Pathogenesis, Yale School of Medicine, US).

FP7 Partnering

Xbrane Bioscience seeks partnerships for participation in the FP7 program: HEALTH 2010. We have knowledge and expertise to contribute to projects within the following calls:

HEALTH.2010.2.3.2-1: Target characterisation and hit-to-lead progression in tuberculosis (TB) Drug development.

HEALTH.2010.2.3.4-1: Vaccines for childhood bacterial diarrhoeal diseases.

For further information about our research and expertise, do not hesitate to contact us. We are welcoming discussions about any project proposals and consortium ideas.